# US Parathyroid Disorders Market > US Parathyroid Disorders Market Research Report By Type of Disorder (Primary Hyperparathyroidism, Secondary Hyperparathyroidism, Tertiary Hyperparathyroidism), By Treatment Type (Medications, Surgery, Radiation Therapy, Observation), By Diagnosis Method (Blood Tests, Imaging Tests, Biopsies) and By Patient Age Group (Children, Adults, Elderly) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 6.08% - **2024:** $ 417.9 Million - **2025:** $ 443.31 Million - **2035:** $ 800 Million - **Key Players:** Amgen Inc (US), Bristol-Myers Squibb Company (US), Eli Lilly and Company (US), Novartis AG (CH), Pfizer Inc (US), Sanofi S.A. (FR), Teva Pharmaceutical Industries Ltd (IL), AbbVie Inc (US) **Report ID:** MRFR/Pharma/18456-HCR · **Pages:** 100 · **Author:** Satyendra Maurya & Garvit Vyas · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-parathyroid-disorders-market-20003 --- ## Market Summary ## **US Parathyroid Disorders Market Overview** As per MRFR analysis, the US Parathyroid Disorders Market Size was estimated at 415.8 (USD Million) in 2023. The US Parathyroid Disorders Market Industry is expected to grow from 485.5(USD Million) in 2024 to 1,052.4 (USD Million) by 2035. The US Parathyroid Disorders Market CAGR (growth rate) is expected to be around 7.286% during the forecast period (2025 - 2035). ### **Key US Parathyroid Disorders Market Trends Highlighted** The US Parathyroid Disorders Market is experiencing significant trends driven by increasing awareness and diagnosis of parathyroid-related conditions. With the rise in healthcare access, more patients are being screened for disorders, leading to early detection and improved treatment outcomes. The aging population in the US, which is more susceptible to conditions such as hyperparathyroidism, is boosting demand for relevant healthcare services and interventions. Advances in medical technology are also playing a key role, with minimally invasive surgical techniques and innovative pharmacological treatments being developed, enhancing patient care. Opportunities are emerging as providers look to expand treatment options for parathyroid disorders. Given the increase in obesity and chronic kidney diseases, which are risk factors for parathyroid abnormalities, healthcare organizations are focusing on preventive care strategies. The integration of digital health technologies, such as telemedicine and remote patient monitoring, is providing new avenues for patient management and follow-up. Furthermore, collaborations between pharmaceutical companies and healthcare providers are paving the way for the development of novel therapies. In recent times, there has been a noticeable trend towards patient-centric care in the US, with a focus on tailoring treatment plans to individual needs. The demand for education and resources about parathyroid disorders is growing, prompting increased investment in community outreach and support programs. The emphasis on outcomes measurement is also reshaping how treatments are evaluated, as stakeholders evaluate efficacy and patient satisfaction. Overall, the US Parathyroid Disorders Market is evolving through these dynamic factors, resulting in improved management of parathyroid disorders for patients nationwide. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **US Parathyroid Disorders Market Drivers** ### **Rising Prevalence of Parathyroid Disorders in the US** The increasing prevalence of parathyroid disorders, particularly primary hyperparathyroidism, has become a significant driver for the growth of the US [Parathyroid Disorders Market](../../../reports/parathyroid-disorders-market-5451) Industry. According to a study published by the National Institutes of Health, the prevalence of primary hyperparathyroidism in the United States is reported to be around 1 in 1,000 individuals, highlighting a marked increase in diagnoses over the past few decades due to improved screening and awareness. As public health initiatives, such as those implemented by the Centers for Disease Control and Prevention, increase awareness and education regarding parathyroid disorders, more patients are likely to seek medical attention. This trend reflects an essential catalyst for market growth, as it leads to higher demand for diagnostic and therapeutic products targeting these disorders. The aging population, particularly those aged 50 and above, is significantly more prone to these conditions, making this demographic's health management a focal point for healthcare providers and pharmaceutical companies. As a result, leading companies like Amgen and Eli Lilly & Company are actively investing in Research and Development to introduce innovative treatment options, thus enhancing the overall market landscape. ### **Advancements in Diagnostic Technologies** Technological advancements in diagnostic procedures are also driving the US Parathyroid Disorders Market Industry. Innovative diagnostic tools such as parathyroid hormone assays and imaging techniques are being developed to enhance the accuracy and speed of diagnosing parathyroid disorders. A report from the American Association of Clinical Endocrinologists highlights that the introduction of highly sensitive immunoassays has improved the detection rates of parathyroid-related ailments. Furthermore, the rise of telemedicine and remote patient monitoring technologies have made it easier for patients to gain access to diagnostics without the need for physically visiting healthcare settings, thus promoting early intervention. Organizations like the American Thyroid Association are advocating for these advancements, pushing for better diagnostic access across varied demographics, which significantly benefits the market. Such improvements in diagnostics empower healthcare professionals to manage cases efficiently and subsequently trigger higher sales for associated treatment products. ### **Increased Research and Development Investments** An uptick in Research and Development investments in therapies targeting parathyroid disorders is a crucial factor contributing to the growth of the US Parathyroid Disorders Market Industry. Pharmaceutical companies are striving to innovate and develop more effective treatments, driven by the increasing incidence of such disorders. According to the National Institutes of Health, funding for biomedical research aimed at understanding parathyroid biology and its implications has seen a substantial increase, amounting to several million dollars in recent years. This influx of capital enables research entities to explore new therapeutic pathways and formulations. Leadership from organizations like the Endocrine Society emphasizes the critical need for ongoing research and supports funding initiatives, boosting the likelihood of successful outcomes and new product introductions. As novel therapies receive regulatory approvals and enter the market, they create competitive landscapes that energize growth potentials, resulting in expanded treatment options for patients. ### **Growing Aging Population and Associated Health Risks** The growing aging population in the United States significantly impacts the US Parathyroid Disorders Market Industry, as older adults are more susceptible to various disorders, including those related to the parathyroid glands. The U.S. Census Bureau reports that by 2030, all baby boomers will be older than 65, which corresponds to an increased incidence of health issues, including osteoporosis and parathyroid disorders. This reinforces the urgency and need for effective management solutions, directly driving market demand. The American Geriatrics Society is actively promoting awareness in treating age-related conditions, thereby increasing the consumer base for treatments related to parathyroid disorders. As healthcare systems are increasingly focused on managing chronic diseases in older adults, pharmaceutical companies are positioned to capitalize on this demographic shift by offering tailored therapeutics targeted at this vulnerable population. ## **US Parathyroid Disorders Market Segment Insights** ### **Parathyroid Disorders Market Type of Disorder Insights** The US Parathyroid Disorders Market exhibits a notable segmentation based on the type of disorder, which significantly contributes to understanding the dynamics within the industry. The market encompasses various types of parathyroid disorders, predominantly Primary Hyperparathyroidism, Secondary Hyperparathyroidism, and Tertiary Hyperparathyroidism. In the context of Primary Hyperparathyroidism, this condition leads to the overproduction of parathyroid hormone, often resulting in high calcium levels in the blood, which is a key health concern for many individuals in the United States. The prevalence of this disorder can be attributed to multiple factors including aging populations and increasing incidences of metabolic bone diseases. Meanwhile, Secondary Hyperparathyroidism arises as a compensatory response to low calcium levels, commonly associated with chronic kidney disease. This condition often emerges in populations suffering from renal dysfunction, highlighting an essential health challenge as chronic kidney diseases are on the rise in the US, thus generating a need for effective treatment options. Furthermore, Tertiary Hyperparathyroidism, which typically follows prolonged Secondary Hyperparathyroidism, represents another critical aspect of the market. Individuals with this disorder often require surgical intervention to correct the hormonal imbalance, underscoring the importance of specialized healthcare services in managing these conditions. The current understanding of these disorders drives significant discussions around prevention and treatment strategies, and healthcare providers are increasingly focused on early diagnosis and management. The combination of different disorders within the Parathyroid Disorders Market reveals a complex landscape that reflects broader health trends in the US. Market growth is further spurred by rising awareness of these disorders, improvements in diagnostic capabilities, and advances in treatment options, ultimately addressing a pressing healthcare need. The growing healthcare expenditure in the United States, particularly relating to chronic diseases, emphasizes the importance of addressing parathyroid disorders. As healthcare systems adapt, there are increased opportunities for innovative treatment solutions that can manage symptoms effectively while improving patients' quality of life. Overall, the segmentation into these distinct disorders underscores the multifaceted nature of parathyroid health issues, providing a framework for market analysis and strategic planning in the US Parathyroid Disorders Market. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **Parathyroid Disorders Market Treatment Type Insights** The Treatment Type segment of the US Parathyroid Disorders Market encompasses various approaches used to manage parathyroid disorders, which are becoming increasingly prevalent in the region. The segment is broadly categorized into Medications, Surgery, Radiation Therapy, and Observation, each playing crucial roles in patient management. Medications often serve as a frontline therapy, providing symptomatic relief and addressing underlying metabolic abnormalities, which is essential for many patients. Surgery remains a dominant approach, particularly for those with primary hyperparathyroidism, where the removal of abnormal parathyroid tissue can lead to long-term resolution of symptoms. Radiation Therapy is employed selectively for patients unable to undergo surgery or as adjuvant treatment, showcasing the importance of personalized care in this market. Additionally, Observation is a conservative strategy commonly utilized in cases of asymptomatic patients, reflecting a growing trend towards minimizing intervention unless necessary. The evolving landscape highlights the significance of tailored treatment based on individual patient needs and conditions while underscoring the importance of comprehensive management strategies in the US Parathyroid Disorders Market. Overall, this segment not only addresses clinical efficacy but also aligns with ongoing advancements in medical technology and patient care protocols, ensuring optimal outcomes for affected individuals. ### **Parathyroid Disorders Market Diagnosis Method Insights** The Diagnosis Method segment of the US Parathyroid Disorders Market plays a critical role in the detection and management of parathyroid disorders. With advancements in medical technology, Blood Tests are becoming pivotal as they provide essential biochemical data, enabling clinicians to evaluate calcium and parathyroid hormone levels effectively. Imaging Tests, including ultrasound and CT scans, are significant as they help in visualizing the glands and identifying any abnormal growths, aiding in precise diagnosis. Biopsies offer definitive insights by enabling pathological examination of any suspicious tissues. The importance of these diagnostic methods is underscored by the rising prevalence of parathyroid disorders in the US, fueled by increasing awareness and advancements in diagnostic techniques. These diagnostic methods contribute substantially to the early detection and effective treatment of conditions, thus enhancing patient outcomes and driving the overall growth of the US Parathyroid Disorders Market. As awareness continues to grow among healthcare professionals and patients alike regarding the importance of early diagnosis, the demand for these diagnostic methods is likely to witness significant momentum. The segment remains central to the market’s overall dynamics, reflecting the ongoing need for efficient and timely diagnosis in the management of parathyroid disorders. ### **Parathyroid Disorders Market Patient Age Group Insights** The Patient Age Group segment within the US Parathyroid Disorders Market showcases a varied landscape that reflects the unique healthcare needs of different age cohorts. Children, often impacted by genetic disorders affecting parathyroid function, represent a crucial demographic that necessitates specialized care approaches tailored to pediatric patients. Adults typically face parathyroid disorders linked to lifestyle factors and other health conditions, showcasing a significant prevalence in this age group, as they may experience complications associated with calcium metabolism and parathyroid hormone imbalance. The elderly population, meanwhile, dominates this segment due to age-related conditions such as primary hyperparathyroidism, which is a common affliction impacting overall wellness and quality of life. Understanding the diverse needs across these segments enables healthcare providers to formulate effective treatment strategies and allocate resources accordingly, highlighting the importance of targeted interventions and ongoing research in the US Parathyroid Disorders Market. As the population continues to age, the challenges and opportunities within this market segment are expected to evolve, indicating a need for healthcare innovation and adaptability. ## **US Parathyroid Disorders Market Key Players and Competitive Insights** The US Parathyroid Disorders Market has emerged as a significant segment within the broader healthcare landscape, driven by increasing prevalence of parathyroid conditions and heightened awareness among both patients and healthcare professionals. This market is characterized by a mix of established pharmaceutical companies and emerging players who are actively engaged in the development, manufacturing, and marketing of therapeutics aimed at managing parathyroid disorders. Competitive dynamics in this sector are influenced by factors such as innovation in drug formulations, regulatory approvals, pricing strategies, and the ability to maintain a strong market presence amidst evolving healthcare policies. Companies operating within this market are constantly vying for competitive advantages, focusing on research and development to enhance their product portfolios and align with patient needs while addressing the challenges presented by generic competition and market entry barriers. Teva Pharmaceutical Industries plays a significant role in the US Parathyroid Disorders Market, with a strong focus on providing innovative treatment options for patients suffering from these conditions. The company is known for its extensive experience in the pharmaceutical industry, which enables it to leverage its capabilities in efficiently developing therapies that target specific parathyroid issues. Teva’s strengths lie in its established distribution networks and a reputation for manufacturing high-quality medications. Furthermore, the company has a robust pipeline of generic and branded products that cater to the needs of healthcare providers and patients alike, which positions it favourably against competitors in the US market. Its commitment to research and development emphasizes not only existing conditions but emerging therapeutic solutions, allowing the company to adapt to changing patient requirements and market conditions effectively. Bristol Myers Squibb is another notable company within the US Parathyroid Disorders Market, distinguished by its strong focus on biopharmaceuticals and advanced therapeutic solutions. The company's involvement in parathyroid disorders is supported by an innovative portfolio that includes a range of key products benefiting patients with calcium metabolism and other related issues. Bristol Myers Squibb has fostered its market presence through strategic mergers and acquisitions that enhance its capabilities in therapeutic development, allowing for a more extensive reach within the healthcare sector. The company's strength lies in its relentless pursuit of new scientific advancements and collaborations, which drive the development of groundbreaking therapies. By engaging in partnerships and strategic alliances, the company strengthens its market position and enhances its research capabilities, which ultimately contributes to improved patient outcomes in the realm of parathyroid disorders across the United States. ### **Key Companies in the US Parathyroid Disorders Market Include** - Teva Pharmaceutical Industries - Bristol Myers Squibb - AstraZeneca - Zymeworks - Eli Lilly and Company - Regeneron Pharmaceuticals - Horizon Therapeutics - Sarepta Therapeutics - MediWound - KalVista Pharmaceuticals - Amgen - **[AbbVie](https://www.abbvie.com/patients/products.html)** - Sanofi - Catalyst Pharmaceuticals - Evoke Pharma ## **US Parathyroid Disorders Market Industry Developments** The US Parathyroid Disorders Market has seen notable advancements recently, particularly concerning drug development and therapeutic interventions. Teva Pharmaceutical Industries and AstraZeneca continue to drive innovative approaches to managing parathyroid disorders, reflecting a shift towards precision medicine. In addition, Bristol Myers Squibb and Amgen reported substantial growth in their parathyroid-related treatments, contributing to an overall market valuation increase. During August 2023, Regeneron Pharmaceuticals made headlines for launching a clinical trial focusing on a groundbreaking therapy for Hyperparathyroidism, showcasing its commitment to enhancing patient outcomes. Meanwhile, Eli Lilly and Company announced a partnership in July 2023 with Horizon Therapeutics to further explore treatment landscapes for parathyroid conditions, solidifying their combined market presence. Although no major mergers or acquisitions occurred specifically within these companies in recent months, the competitive landscape remains robust as firms like Zymeworks and Catalyst Pharmaceuticals strategize for market entry. Historical developments reveal that in April 2022, MediWound expanded its research efforts, emphasizing new treatment protocols for parathyroid disorders. Overall, these movements indicate a dynamic and evolving market poised for further growth and innovation in the coming years. ## **US Parathyroid Disorders Market Segmentation Insights** ### **Parathyroid Disorders Market Type of Disorder Outlook** - Primary Hyperparathyroidism - Secondary Hyperparathyroidism - Tertiary Hyperparathyroidism ### **Parathyroid Disorders Market Treatment Type Outlook** - Medications - Surgery - Radiation Therapy - Observation ### **Parathyroid Disorders Market Diagnosis Method Outlook** - Blood Tests - Imaging Tests - Biopsies ### **Parathyroid Disorders Market Patient Age Group Outlook** - Children - Adults - Elderly ## Market Drivers ### Advancements in Surgical Techniques Innovations in surgical techniques for treating parathyroid disorders are significantly impacting the parathyroid disorders market. Minimally invasive procedures, such as video-assisted parathyroidectomy, have gained traction due to their reduced recovery times and lower complication rates. The American Association of Endocrine Surgeons reports that these techniques can lead to shorter hospital stays and quicker patient recovery, which is appealing to both patients and healthcare providers. As surgical methods continue to evolve, the demand for specialized surgical instruments and training will likely rise, contributing to the overall growth of the parathyroid disorders market. ### Growing Demand for Diagnostic Testing The demand for accurate and timely diagnostic testing for parathyroid disorders is on the rise, significantly influencing the parathyroid disorders market. As awareness of these conditions increases, healthcare providers are prioritizing early detection and intervention. The market for diagnostic tests, including serum calcium and parathyroid hormone assays, is projected to grow as more patients seek evaluation for symptoms related to parathyroid dysfunction. According to market analysis, the diagnostic segment is expected to account for a substantial share of the parathyroid disorders market, driven by advancements in testing technologies and increased healthcare expenditure. ### Rising Incidence of Parathyroid Disorders The increasing prevalence of parathyroid disorders in the US is a notable driver for the parathyroid disorders market. Conditions such as primary hyperparathyroidism and secondary hyperparathyroidism are becoming more common, particularly among older adults. According to the National Institutes of Health, the incidence of primary hyperparathyroidism is estimated to be around 1-4 cases per 1,000 individuals, with a higher occurrence in women. This rising incidence necessitates enhanced diagnostic and therapeutic options, thereby propelling the parathyroid disorders market forward. As healthcare providers seek to address this growing patient population, investments in research and development are likely to increase, further stimulating market growth. ### Aging Population and Associated Health Issues The aging population in the US is a critical driver for the parathyroid disorders market. As individuals age, the risk of developing parathyroid disorders, particularly primary hyperparathyroidism, increases. The US Census Bureau projects that by 2030, nearly 20% of the population will be 65 years or older, leading to a higher prevalence of age-related health issues. This demographic shift is likely to result in increased healthcare utilization, including diagnostic and therapeutic services for parathyroid disorders. Consequently, healthcare systems may need to adapt to accommodate the growing needs of this population, further propelling the parathyroid disorders market. ### Increased Investment in Research and Development The parathyroid disorders market is experiencing a surge in investment directed towards research and development. Pharmaceutical companies and biotech firms are focusing on developing novel therapies and diagnostic tools for parathyroid disorders. The National Institutes of Health has allocated substantial funding for research aimed at understanding the underlying mechanisms of these disorders, which could lead to innovative treatment options. This influx of investment is expected to enhance the availability of effective therapies, thereby expanding the parathyroid disorders market. Furthermore, collaborations between academic institutions and industry players may foster breakthroughs that could reshape treatment paradigms. ## Future Outlook The [Parathyroid Disorders Market](https://www.marketresearchfuture.com/reports/parathyroid-disorders-market-5451) is projected to grow at a 6.08% CAGR from 2025 to 2035, driven by advancements in diagnostics, increasing prevalence, and innovative treatment options. **New opportunities:** - Development of targeted therapies for hyperparathyroidism - Expansion of telehealth services for patient monitoring - Investment in AI-driven diagnostic tools for early detection By 2035, the market is expected to achieve substantial growth, reflecting evolving treatment paradigms and increased patient access. ## Segment Insights ### By Type of Disorder: Primary Hyperparathyroidism (Largest) vs. Secondary Hyperparathyroidism (Fastest-Growing) In the US parathyroid disorders market, Primary Hyperparathyroidism represents the largest share among the disorder types, reflecting its prevalence and notable clinical importance. This segment is characterized by excessive parathyroid hormone production leading to elevated calcium levels in the blood. On the other hand, Secondary Hyperparathyroidism, while smaller in market share, has shown significant growth trends due to increasing incidence linked to chronic kidney disease, compelling healthcare providers to focus on it more than ever. Growth trends for the Type of Disorder segment indicate that Secondary Hyperparathyroidism is on a rapid upward trajectory, driven by rising awareness and improvements in diagnostic technologies. Furthermore, the aging population in the US is likely to contribute to higher prevalence rates of parathyroid disorders overall. Advances in treatment protocols and patient education also play crucial roles in increasing the adoption of therapies for these conditions, particularly for those facing Secondary Hyperparathyroidism. Primary Hyperparathyroidism (Dominant) vs. Secondary Hyperparathyroidism (Emerging) Primary Hyperparathyroidism stands as the dominant player in the US parathyroid disorders market, arising mainly from benign tumors on the parathyroid glands. Its symptoms, including osteoporotic fractures and kidney stones, create a significant burden on the healthcare system, necessitating ongoing treatments and interventions. In contrast, Secondary Hyperparathyroidism is classified as an emerging segment, primarily developing in response to low calcium levels due to chronic kidney dysfunction. As awareness grows and more individuals seek medical help for kidney-related issues, the market for Secondary Hyperparathyroidism treatments is expanding rapidly. This increase underscores the need for innovative therapeutic approaches and healthcare strategies to accommodate the rising patient base and to manage this evolving disorder effectively. ### By Treatment Type: Medications (Largest) vs. Surgery (Fastest-Growing) Within the US parathyroid disorders market, the treatment type segment showcases a diverse range of options, with medications holding the largest share. Medications provide a broad spectrum of treatments, effectively managing various symptoms and conditions associated with parathyroid disorders. Surgery, while currently a smaller fraction of the market, is rapidly gaining ground due to technological advancements and increasing awareness among clinicians and patients alike. The growth forecast for these treatment types indicates a dynamic shift in patient preferences, particularly towards minimally invasive surgical options. The demand for effective medications remains strong as they cater to a larger patient demographic. Surgery is anticipated to experience significant growth driven by innovations in surgical methods and improved patient outcomes, solidifying its role in the treatment landscape. Medications (Dominant) vs. Surgery (Emerging) In the treatment landscape of the US parathyroid disorders market, medications are recognized as the dominant force, providing comprehensive treatment for patients with varying needs. These solutions offer versatility and accessibility, making them a preferable choice for many individuals seeking management of their condition. Conversely, surgery is positioned as an emerging option that is attracting increasing interest due to its potential for curative outcomes. Advances in surgical techniques and safety have improved the appeal of surgical interventions, making it a viable option for patients who do not respond adequately to pharmacological treatments. This evolving dynamic between medications and surgery reflects the ongoing advancements and shifts in treatment paradigms in the market. ### By Diagnosis Method: Blood Tests (Largest) vs. Imaging Tests (Fastest-Growing) In the US parathyroid disorders market, the segment values for diagnosis methods exhibit a varied distribution of market share. Blood tests currently hold the largest share, driven by their established use in the initial assessment of parathyroid disorders. Imaging tests follow, gaining traction particularly as technology advances, leading to more precise diagnostics. Biopsies remain a crucial but less common method, primarily employed when other tests indicate a need for confirmation. Growth trends in this segment are promising, especially for imaging tests, which are experiencing rapid expansion. The drive towards minimally invasive procedures and the introduction of advanced imaging technologies are propelling this growth. Blood tests continue to dominate due to their low cost and accessibility. Overall, the diagnosis method segment is expanding as healthcare providers seek more accurate and efficient patient management strategies. Blood Tests (Dominant) vs. Biopsies (Emerging) Blood tests are the dominant method in the diagnosis of parathyroid disorders, valued for their efficiency, cost-effectiveness, and ability to provide immediate results. They serve as the first-line diagnostic tool for clinicians assessing parathyroid function. On the other hand, biopsies, while still considered an emerging method, have gained significance for their role in confirming diagnoses when blood tests and imaging provide inconclusive results. Though less common, the application of biopsies is critical in complex cases, as they yield definitive information regarding parathyroid tissue. This dynamic highlights the balance between widely used diagnostic approaches and more specialized, albeit less frequent, methodologies. ### By Patient Age Group: Adults (Largest) vs. Elderly (Fastest-Growing) In the US parathyroid disorders market, the segment distribution shows that Adults dominate the patient age group, holding the largest share. The prevalence of parathyroid disorders in this demographic is attributed to factors such as lifestyle diseases, which are more common in adults. Children represent a smaller fraction, with relatively low incidence rates, while the Elderly segment is witnessing a substantial rise in cases due to aging populations. Growth trends indicate that the Elderly segment is becoming the fastest-growing demographic as the population ages and becomes more susceptible to parathyroid disorders. Increased awareness among healthcare providers and improved diagnostic techniques are also contributing to the rising incidence in this group. As healthcare technology advances, both Adults and the Elderly are expected to see enhanced treatment options, driving market dynamics further. Adults (Dominant) vs. Elderly (Emerging) In the US parathyroid disorders market, Adults are recognized as the dominant group, characterized by higher prevalence rates and better access to medical care. This segment typically shows a greater demand for treatment options due to the lifestyle-related risks that lead to parathyroid disorders. On the other hand, the Elderly population is emerging as a critical focus area, facing various health challenges due to age-related factors. Their increasing number in healthcare statistics is prompting further research into tailored treatments that can address the specific needs of older patients. As a result, targeting these two age groups is essential for market players aiming to enhance their product offerings and strategically position themselves in the competitive landscape. ## Competitive Benchmarking This market is characterized by a competitive landscape that is increasingly shaped by innovation, strategic partnerships, and a focus on patient-centric solutions. Key players such as Amgen Inc (US), Eli Lilly and Company (US), and Pfizer Inc (US) are actively engaged in enhancing their product portfolios and expanding their market reach. Amgen Inc (US) has positioned itself as a leader in the development of novel therapies, particularly focusing on biologics that target parathyroid hormone pathways. Meanwhile, Eli Lilly and Company (US) emphasizes its commitment to research and development, aiming to introduce cutting-edge treatments that address unmet medical needs in parathyroid disorders. Pfizer Inc (US) is also notable for its strategic collaborations with academic institutions to foster innovation in treatment modalities, thereby enhancing its competitive edge.The business tactics employed by these companies reflect a concerted effort to optimize supply chains and localize manufacturing processes. The market structure appears moderately fragmented, with a mix of established pharmaceutical giants and emerging biotech firms. This fragmentation allows for a diverse range of treatment options, although the influence of major players remains substantial. The collective strategies of these key companies contribute to a dynamic environment where innovation and operational efficiency are paramount. In October Amgen Inc (US) announced a strategic partnership with a leading biotech firm to co-develop a new parathyroid hormone analog aimed at improving patient outcomes in hypoparathyroidism. This collaboration is expected to leverage both companies' expertise in biologics, potentially accelerating the development timeline and enhancing market access. Such partnerships are indicative of a broader trend towards collaborative innovation in the sector. In September Eli Lilly and Company (US) launched a new digital health platform designed to support patients with parathyroid disorders by providing personalized treatment plans and real-time monitoring. This initiative not only underscores the company's commitment to patient engagement but also reflects a growing trend towards digitalization in healthcare, which is likely to enhance treatment adherence and outcomes. In August Pfizer Inc (US) expanded its clinical trial program for a novel parathyroid hormone therapy, focusing on diverse patient populations across the US. This strategic move is significant as it aims to gather comprehensive data that could support regulatory approvals and broaden the therapy's applicability, thereby enhancing Pfizer's market position. As of November the competitive trends in the parathyroid disorders market are increasingly influenced by digital transformation, sustainability initiatives, and the integration of artificial intelligence in drug development. Strategic alliances are becoming more prevalent, fostering innovation and enhancing the ability to respond to market demands. Looking ahead, it appears that competitive differentiation will increasingly hinge on technological advancements and the reliability of supply chains, shifting the focus from traditional price-based competition to a more nuanced approach centered on innovation and patient-centric solutions. ## Recent News & Developments The US Parathyroid Disorders Market has seen notable advancements recently, particularly concerning drug development and therapeutic interventions. Teva Pharmaceutical Industries and AstraZeneca continue to drive innovative approaches to managing parathyroid disorders, reflecting a shift towards precision medicine. In addition, Bristol Myers Squibb and Amgen reported substantial growth in their parathyroid-related treatments, contributing to an overall market valuation increase. During August 2023, Regeneron Pharmaceuticals made headlines for launching a clinical trial focusing on a groundbreaking therapy for Hyperparathyroidism, showcasing its commitment to enhancing patient outcomes. Meanwhile, Eli Lilly and Company announced a partnership in July 2023 with Horizon Therapeutics to further explore treatment landscapes for parathyroid conditions, solidifying their combined market presence. Although no major mergers or acquisitions occurred specifically within these companies in recent months, the competitive landscape remains robust as firms like Zymeworks and Catalyst Pharmaceuticals strategize for market entry. Historical developments reveal that in April 2022, MediWound expanded its research efforts, emphasizing new treatment protocols for parathyroid disorders. Overall, these movements indicate a dynamic and evolving market poised for further growth and innovation in the coming years. ## Report Scope | MARKET SIZE 2024 | 417.9(USD Million) | | --- | --- | | MARKET SIZE 2025 | 443.31(USD Million) | | MARKET SIZE 2035 | 800.0(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.08% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Amgen Inc (US), Bristol-Myers Squibb Company (US), Eli Lilly and Company (US), Novartis AG (CH), Pfizer Inc (US), Sanofi S.A. (FR), Teva Pharmaceutical Industries Ltd (IL), AbbVie Inc (US) | | Segments Covered | Type of Disorder, Treatment Type, Diagnosis Method, Patient Age Group | | Key Market Opportunities | Advancements in minimally invasive surgical techniques enhance treatment options in the parathyroid disorders market. | | Key Market Dynamics | Rising demand for innovative therapies drives competition and regulatory scrutiny in the parathyroid disorders market. | | Countries Covered | US | ## Frequently Asked Questions **Q: What was the overall market valuation for parathyroid disorders in 2024?** A: The overall market valuation for parathyroid disorders was $417.9 Million in 2024. **Q: What is the projected market valuation for parathyroid disorders by 2035?** A: The projected market valuation for parathyroid disorders is $800.0 Million by 2035. **Q: What is the expected CAGR for the US parathyroid disorders market during the forecast period 2025 - 2035?** A: The expected CAGR for the US parathyroid disorders market during the forecast period 2025 - 2035 is 6.08%. **Q: Which companies are considered key players in the parathyroid disorders market?** A: Key players in the parathyroid disorders market include Amgen Inc, Bristol-Myers Squibb Company, Eli Lilly and Company, Novartis AG, Pfizer Inc, Sanofi S.A., Teva Pharmaceutical Industries Ltd, and AbbVie Inc. **Q: What are the market segments for parathyroid disorders based on the type of disorder?** A: The market segments based on the type of disorder include Primary Hyperparathyroidism ($200.0 - $400.0 Million), Secondary Hyperparathyroidism ($150.0 - $300.0 Million), and Tertiary Hyperparathyroidism ($67.9 - $100.0 Million). **Q: What treatment types are available for parathyroid disorders and their market valuations?** A: Available treatment types include Medications ($100.0 - $200.0 Million), Surgery ($150.0 - $300.0 Million), Radiation Therapy ($50.0 - $100.0 Million), and Observation ($117.9 - $200.0 Million). **Q: What diagnostic methods are utilized in the parathyroid disorders market?** A: Diagnostic methods include Blood Tests ($150.0 - $300.0 Million), Imaging Tests ($200.0 - $400.0 Million), and Biopsies ($67.9 - $100.0 Million). **Q: How is the patient age group segmented in the parathyroid disorders market?** A: The patient age group segmentation includes Children ($50.0 - $100.0 Million), Adults ($250.0 - $500.0 Million), and Elderly ($117.9 - $200.0 Million). **Q: What does the market outlook for parathyroid disorders suggest for the future?** A: The market outlook for parathyroid disorders suggests a robust growth trajectory, with a projected valuation of $800.0 Million by 2035. **Q: How do the treatment and diagnosis segments compare in terms of market valuation?** A: The treatment segment, particularly Surgery, is projected to have a higher valuation ($150.0 - $300.0 Million) compared to the diagnosis segment, with Imaging Tests valued at $200.0 - $400.0 Million. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-parathyroid-disorders-market-20003*